New Clinical and Real-World Evidence for Alzheimer's Treatment Lecanemab Scheduled for CTAD 2026

Overview of Upcoming Presentations

BioArctic AB's partner, Eisai, is scheduled to present new clinical trial and real-world evidence regarding the Alzheimer's disease treatment lecanemab (marketed as Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations, running from November 16 to November 19, 2026, will feature long-term outcomes, including five-year data from the Clarity AD study and findings from the retrospective, multicenter LEADER study evaluating real-world clinical usage across diverse United States settings.

The upcoming disclosures encompass a broad spectrum of research topics, ranging from safety profiles and amyloid-beta management to subcutaneous administration methods and biomarker analyses. BioArctic is also slated to present a distinct poster focusing on the binding profile of lecanemab.

Key Research Areas and Studies

The scientific program at CTAD features several primary data categories:

• Clarity AD Long-Term Extension: A featured oral presentation will deliver findings through 60 months of treatment, representing one of the longest continuous follow-up datasets reported for an approved anti-amyloid therapy.
• LEADER Study Analyses: Multiple presentations will examine real-world utilization, safety data, sex-based outcomes, and at-home subcutaneous administration three years following the U.S. Food and Drug Administration (FDA) approval.
• Safety and Biomarkers: Meta-analyses concerning Amyloid-Related Imaging Abnormalities (ARIA) rates across multiple countries, alongside cerebrospinal fluid (CSF) substudies examining alpha-synuclein co-pathology and proteome-wide central nervous system remodeling.

Background and Regulatory Status

Lecanemab is a humanized monoclonal antibody targeted against aggregated soluble protofibrils and insoluble forms of amyloid-beta. Developed through a strategic alliance between BioArctic and Eisai—with Eisai managing global clinical development and commercialization—the therapy is approved in 53 countries and regions. Maintenance dosing regimens, including intravenous and subcutaneous options via autoinjector devices, have secured varying levels of international regulatory clearance and review.

Practical Implications and Verification

Readers, medical professionals, and researchers tracking neurodegenerative disease treatments can review the official disclosures and conference abstracts directly through the primary corporate announcement.

• What is Confirmed: Eisai will present findings from the Clarity AD and LEADER studies at the CTAD 2026 conference in Boston. The scope includes five-year follow-up data, real-world utilization trends, and subcutaneous delivery evaluations.
• What Remains Unknown: Specific quantitative clinical efficacy endpoints, detailed safety metrics, and peer-reviewed journal publications for these specific conference abstracts have not been fully detailed outside the initial announcement framework.
• How to Verify: Interested parties can examine the official press release and associated Cision disclosures published by BioArctic AB at their designated investor relations portal or via the source link below.

Source: [PR Newswire / BioArctic Official Announcement](https://www.prnewswire.com/news-releases/new-clinical-data-on-lecanemab-to-be-presented-at-ctad-conference-2026-302924707.html)